UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-31911 American National Group Inc. (Exact name of Registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q (Mark One) Delaware 42-1447959 ...

Exhibit 99.1 NextPlat Reports First Quarter 2025 Results Company Reports $14.5M in Q1 Revenue; Operating Expenses Decline 26% as Expected, with Continued Focus on Cost Reduction, Ef iciency Improvements, and Strategic Planning Amid Rising Drug Prices and Potential Tarif Impacts COCONUT GROVE, FL – May 15, 2025 – NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the financial results for the quarter-ended March 31, 2025, reflecting the performanc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ________ to ________ Commission File Number: 001-08032 SAN JUAN BASIN ROYALTY TRUST (Exact name of registrant as specified in its charter) (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR | | | Name of Each Exchange On Which | | --- | --- | --- | | Title of Each Class | Trading Symbol(s) | Registered | | Common Stock, par v ...

公司整体财务数据关键指标变化 - 2024财年公司收入同比增长32.9%，达到2834万美元，主要得益于战略扩张和运营实力[3][5] - 2024财年公司毛利润为918.5万美元，低于2023财年的934.4万美元，主要因直接患者服务业务运营成本增加[7] - 2024财年公司税前收入同比增长77.7%，达到123.7万美元，主要源于罗德岛收购的廉价购买收益[8] - 2024财年归属于公司的净利润同比增长258.4%，达到218.6万美元，摊薄后每股收益为0.34美元[3][9] - 2024财年调整后EBITDA同比增长8.5%，达到888.5万美元[3][10] - 2024年第四季度收入同比增长59.2%，达到906.9万美元，得益于放疗服务的扩展[11] - 截至2024年12月31日，公司现金、现金等价物和受限现金总计1127.5万美元，低于2023年的1380.8万美元；股东权益（不包括非控股权益）为2518.3万美元，高于2023年的2262.4万美元[16][26] - 2024年第四季度净亏损130.8万美元，2023年同期净利润41.5万美元[28] - 2024年全年净利润218.6万美元，2023年为61万美元[28] - 2024年第四季度所得税收益7.1万美元，2023年同期费用33.8万美元[28] - 2024年全年所得税收益29.5万美元，2023年费用43.1万美元[28] - 2024年第四季度利息费用42.9万美元，2023年同期28.7万美元[28] - 2024年全年利息费用149.9万美元，2023年111.2万美元[28] - 2024年第四季度折旧和摊销费用167.3万美元，2023年同期129.1万美元[28] - 2024年全年折旧和摊销费用617.4万美元，2023年516.5万美元[28] - 2024年第四季度调整后EBITDA为346.4万美元，2023年同期267.9万美元[28] - 2024年全年调整后EBITDA为888.5万美元，2023年818.9万美元[28] 各条业务线数据关键指标变化 - 2024财年直接患者服务收入同比增长253.4%，达到1255.6万美元；租赁业务收入同比下降12.1%，为1562.9万美元[3][5] - 2024财年质子治疗收入同比下降1.8%，为995.2万美元，治疗次数下降4.3%至5139次[6] - 2024年第四季度直接患者服务收入同比增长420.2%，达到474.9万美元；医疗设备租赁业务收入为432万美元，低于2023年第四季度的478.5万美元[12]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | ...

or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 Commission File Number 0-10843 CSP Inc. (Exact name of Registrant as specified in its charter) Massachusetts 04-2441294 (State or other jurisdicti ...

As filed with the Securities and Exchange Commission on May 15, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT T ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40511 Moving iMage Technologies, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdictio ...